Maternal T Cell Engraftment in SCID, Pre-Engraftment Specimen
Also known as: SCID-PRE
Use
This test is used to monitor engraftment of maternal T cells in patients with severe combined immunodeficiency (SCID) prior to allogenic stem cell transplantation. SCID patients lack T cells and cannot recognize and reject maternal T cells from maternal-fetal transfusion. Maternal T cells can proliferate in the absence of host T cells, leading to difficulty in determining the host T cell numbers required for the diagnosis of SCID and can cause graft-versus-host disease-line (GVHD) presentation.
Special Instructions
To complete testing, samples should be collected for three tests: a buccal brush from the patient for genetic baseline, a peripheral blood sample from the biological mother for maternal genetic baseline, and a peripheral blood sample from the patient for comparison to baseline genotypes. Additional charges apply for cell isolation if T-cell sorting is not completed before submission.
Limitations
Diagnostic errors can occur due to rare sequence variations. The test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration and is performed in a CLIA-certified laboratory for clinical purposes.
Methodology
PCR-based (PCR)
Biomarkers
Result Turnaround Time
5-9 days
Related Documents
For more information, please review the documents below
Specimen
Buccal Swab
Volume
Not provided
Minimum Volume
Not provided
Container
dry, sterile container
Collection Instructions
Collect 3-4 brush samples from patient and place in a dry, sterile container for transport.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 1 week |
| Refrigerated | 1 month |
| Frozen | unacceptable |
Other tests from different labs that may be relevant